


Stabilis



Nafcillin sodium



Noms commerciaux

Nafcillin	Etats Unis d'Amérique, Turquie
Unipen	Canada



Stabilité des solutions

PVC		20 & 120 mg/ml	25°C	?	3			13
PVC		20 & 120 mg/ml	5°C		14			13
PVC		20 mg/ml	-20°C		30			575
EVA		10 mg/ml	23°C		5			1705
EVA		10 mg/ml	4°C		14			1705
		250 mg/ml	-20°C		270			574
		10 mg/ml	25°C	?	7			2352
		10 mg/ml	5°C	?	44			2352


























































Facteur influençant la stabilité

				2005
--	--	--	--	------



Compatibilités

			
			3549
			3580
			198
			999
			3547
			3529
			1415
			336
			1366
			433
			4154
			2247
			1366
			198
			1366
			1315
			301
			3674
			384
			397
			3503
			1366
			496
			1135

		Nafcillin sodium Gentamicin sulfate		3643
		Nafcillin sodium Gentamicin sulfate		3520
		Nafcillin sodium : 20 mg/ml Heparin sodium : 50 UI/ml		317
		Nafcillin sodium : 20 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Nafcillin sodium : 20 & 40 mg/ml Insulin : 0.2 UI/ml		129
		Nafcillin sodium : 10 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Nafcillin sodium : 20 mg/ml Lidocaine hydrochloride : 0,6 mg/ml		278
		Nafcillin sodium : 20 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml		1047
		Nafcillin sodium : 5 mg/ml Magnesium sulfate : 10 & 20 mg/ml		630
		Nafcillin sodium : 20 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Nafcillin sodium : 20 & 30 mg/ml Morphine sulfate : 1 mg/ml		406
		Nafcillin sodium : 20 mg/ml Morphine sulfate : 1 mg/ml		405
		Nafcillin sodium : 33 mg/ml Nalbuphine hydrochloride : 10 mg/ml		1366
		Nafcillin sodium : 10 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Nafcillin sodium : 20 & 30 mg/ml Pethidine hydrochloride : 10 mg/ml		406
		Nafcillin sodium : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Nafcillin sodium : 20 mg/ml Propofol : 10 mg/ml		300
		Nafcillin sodium : 20 mg/ml Theophylline : 4 mg/ml		317
		Nafcillin sodium : 10 >> 250 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674
		Nafcillin sodium : 10 >> 250 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Nafcillin sodium : 1 mg/ml Vancomycin hydrochloride : 2 & 20 mg/ml		1674
		Nafcillin sodium : 4 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057
		Nafcillin sodium : 40 mg/ml Verapamil hydrochloride : 2.5 mg/ml		371
		Nafcillin sodium Verapamil hydrochloride		1099
		Nafcillin sodium Verapamil hydrochloride		1351
		Nafcillin sodium : 20 mg/ml Zidovudine : 4 mg/ml		337



Voie d'administration



Bibliographie

	Type	Source
13	Revue	Stiles ML, Allen LV. Stability of nafcillin sodium, oxacillin sodium, penicillin G potassium, penicillin G sodium and tobramycin sulfate in polyvinyl chloride drug reservoirs. Am J Health-Syst Pharm 1997 ; 54: 1068-1070.
129	Revue	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
198	Revue	Gayed AA, Khesary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
278	Revue	Hagan RL, Carr-Lopez S, Strickland JS. Stability of nafcillin sodium in the presence of lidocaine hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 521-523.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
371	Revue	Thompson DF, Stiles ML, Allen LV, Tu YH. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 142-145.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.

397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
405	Revue	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
406	Revue	Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820.
433	Revue	Riley CM, Lipford LC. Interaction of aztreonam with nafcillin in intravenous admixtures. Am J Hosp Pharm 1986 ; 43: 2221-2224.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
574	Revue	Kleinberg ML, Stauffer GL, Prior RB, Latiolais CJ. Stability of antibiotics frozen and stored in disposable hypodermic syringes. Am J Hosp Pharm 1980 ; 37: 1087-1088.
575	Revue	Holmes CJ, Ausman RK, Kundsinn RB, Walter CW. Effect of freezing and microwave thawing on the stability of six antibiotic admixtures in plastic bags. Am J Hosp Pharm 1982 ; 39: 104-108.
630	Revue	Das Gupta V, Stewart KR. Stability of metronidazole and ten antibiotics when mixed with magnesium sulphate solutions. J Clin Hosp Pharm 1985 ; 10: 67-72.
999	Revue	Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224.
1047	Revue	Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1099	Revue	Tucker R, Gentile JF. Precipitation of verapamil in an intravenous line. Ann Intern Med 1984 ; 101: 880.
1135	Revue	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1351	Revue	Tucker R, Gentle JF. Precipitation of verapamil with nafcillin. Am J Hosp Pharm 1984 ; 41: 2588.
1366	Revue	Jeglum EL, Winter E, Kotos M. Nafcillin sodium incompatibility with acidic solutions. Am J Hosp Pharm 1981 ; 38: 462,464.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.

1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1674	Revue	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1705	Revue	Zhang Y, Trissel LA. Stability of ampicillin sodium, nafcillin sodium, and oxacillin sodium in autodose system bags. Int J Pharm Compound 2002 ; 6: 226-229.
2005	Revue	Chan V. Influence of temperature and drug concentration on nafcillin precipitation. Am J Health-Syst Pharm 2005 ; 62: 1347-1348.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2352	Revue	Ling J, Das Gupta V. Stability of nafcillin sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2000 ; 4, 6: 480-481.
3503	Laboratoire	Fentanyl - Summary of product Characteristics Hameln Pharmaceuticals 2012
3520	Laboratoire	Cidomycin - Summary of product Characteristics. Sanofi 2011
3529	Laboratoire	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3547	Laboratoire	Aztréonam (Azactam®) - Résumé des caractéristiques du produit Sanofi-Aventis France 2011
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3580	Laboratoire	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3643	Laboratoire	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
4154	Laboratoire	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 Eau pour préparation injectable	 Non précisée
 Jour	 A l'abri de la lumière
 Glucose 5%	 Ethylène vinyl acétate
 Chlorure de sodium 0,9%	 Seringue polypropylène
 Facteur influençant la stabilité	 Augmentation
 Provoque	 Précipitation
 Compatibilités	 Molécule
 Solvant	 Instabilité chimique
 Incompatible	 Incompatibilité non précisée
 Turbidité immédiate	 Compatible
 Nutrition parentérale (mélange binaire)	 Nutrition parentérale (mélange ternaire)
 Précipitation en 6 heures	 NaCl 0,9% ou glucose 5%
 Précipitation en 1 heure	 Précipitation immédiate
 Aucun	 Voie d'administration
 Intraveineuse	 Perfusion intraveineuse
 Intramusculaire	 Bibliographie
 Dictionnaire	